Azitra was founded to harness the power of the microbiome to create a new paradigm for treating skin disease. Our work is supported by NIH grants, private grants, and investment from Bios Partners and Breakout labs. We have the privilege of collaborating with leading scientists in the field from Yale University, Jackson Labs, and the University of Connecticut.
Azitra is a preclinical-stage development company using a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease. We are addressing skin conditions ranging from atopic dermatitis to Netherton syndrome to MRSA skin infections using our proprietary bacterial platform engineered to deliver therapetuic proteins.
You have more microbes in and on your body than you do your own cells. Yet, the "microbiome" can be misunderstood even though it plays a critical role in protecting human health. We have developed a platform that harnesses the potential of the microbiome to treat a range of skin diseases.